Contact a rep button
contact a rep

stay connected!

Fill in the required fields to stay up to date with news and announcements about VPRIV.
*Required Field

One or more required fields are invalid.

Please review and submit this form again.

thank you!

You have been successfully signed up to receive
communications from Takeda

Click here to unsubscribe

Hero section background Female patient


VPRIV’s safety and efficacy profile was evaluated in the largest clinical trial program of an ERT for type 1 Gaucher disease1–3

VPRIV was evaluated in 99 patients across three clinical trials, which included pediatric (aged ≥4 years), adult, and geriatric (aged ≥65 years) patients.1 Some of these patients were then enrolled into one phase III, open-label, long-term extension trial conducted in adult and pediatric patients (n=93).1,4

*Treatment-naïve: patients who had not received disease-specific treatment within the 30 months prior to starting VPRIV5,6,8
Treatment-experienced: patients previously treated with imiglucerase for a minimum of 30 consecutive months prior to switching to VPRIV7,9


Hypersensitivity reactions, including anaphylaxis, have occurred. The most serious adverse reactions in patients treated with VPRIV were hypersensitivity reactions.

Hypersensitivity reactions were the most commonly observed adverse reactions in patients treated with VPRIV in clinical studies. Patients were not routinely pre-medicated prior to infusion of VPRIV.